TEL AVIV, Israel and BETHESDA, MD, May 31, 2022 /PRNewswire/ — CNBX Pharmaceuticals Inc. (OTCQB: CNBXD), a global chief in the improvement of cancer associated cannabinoid-centered medicine, introduced currently the release of its up-to-date company presentation, now available on the Firm’s site: https://cnbxpharma.com/investors/
The Firm’s updated corporate presentation demonstrates the Firm’s hottest development pipeline as properly as the team’s ahead-on the lookout approach to molecule-primarily based drug advancement of Neoadjuvant Cure for Colorectal Cancer, and the company’s approach to start a Section I/II (a) scientific validation analyze for Firm’s proprietary RCC-33 drug applicant by end of 2023.
About CNBX Prescription drugs:
CNBX Prescribed drugs Inc. (OTCQB: CNBXD) is a U.S. public organization and a international chief in the growth of cancer associated cannabinoid-primarily based medicine. The Firm’s R&D is centered in Israel, where it is certified by the Ministry of Well being to conduct scientific and medical analysis on cannabinoid formulations and most cancers. For a lot more information and facts, please go to www.cnbxpharma.com
For the hottest updates on CNBX Prescription drugs adhere to the Business on social media:
Selected statements contained in this release may perhaps represent ahead-searching statements in the meaning of the Non-public Securities Litigation Reform Act of 1995 and other U.S. Federal securities legal guidelines. These statements involve but are not constrained to statements recognized by phrases such as “thinks,” “expects,” “anticipates,” “estimates,” “intends,” “options,” “targets,” “initiatives” and related expressions. The statements in this launch are dependent upon the present beliefs and anticipations of our Firm’s management and are subject to sizeable threats and uncertainties. Precise final results may possibly differ from those people outlined in the forward-seeking statements. Quite a few factors could result in or lead to such discrepancies, which include, but not restricted to, success of scientific trials and other scientific tests, the difficulties inherent in new item progress initiatives, the result of any aggressive products, our ability to license and protect our intellectual house, our capability to elevate extra funds in the foreseeable future that is required to sustain our organization, changes in govt plan and regulation, likely litigation by or towards us, any governmental assessment of our solutions or practices, as well as other dangers talked about from time to time in our filings with the Securities and Exchange Commission. We undertake no duty to update any ahead-seeking assertion or any info contained in this push release or other general public disclosures at any time. Ultimately, the investing public is reminded that the only announcements or information about CNBX Prescribed drugs Inc., which are condoned by the Corporation, need to emanate from the Company itself and bear our identify as its source.
Supply CNBX Prescription drugs Inc.